Halozyme Appoints David Ramsay as Interim CFO

SEC 8-K Filing Notice

Company: Halozyme Therapeutics, Inc. (HALO) Filing Date: 2026-03-12 Accession Number: 0001159036-26-000035

Items Filed

Item 5.02: Departure of Directors or Certain Officers; Election of Directors Item 9.01: Financial Statements and Exhibits

Summary

Halozyme Therapeutics announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay previously held CFO and VP roles at Halozyme from 2003-2015 and brings extensive financial and biotech experience, including board positions at Savara Inc. and Exuma Biotech, and a CFO role at Bonti, Inc. before its acquisition by Allergan. This appointment provides Halozyme with experienced financial leadership during the interim period.

Key Takeaways

David Ramsay appointed Interim CFO, effective March 23, 2026.
Ramsay previously served as Halozyme's CFO (2003-2009, 2013-2015) and VP, Corporate Development (2009-2013).
Ramsay's compensation includes a $50,000 monthly salary and 10,000 RSUs vesting June 30, 2026, with a one-year holding period.
Additional 2,500 RSUs granted if Ramsay continues as Interim CFO on July 1, 2026, vesting on termination date with a one-year holding period.
Ramsay has significant experience in the biotech industry, including board positions at Savara Inc. and Exuma Biotech.

Analysis

The appointment of David Ramsay as Interim CFO signals a period of transition for Halozyme's financial leadership. Ramsay's prior experience with the company provides stability and familiarity, which could be reassuring to investors. The equity grants incentivize Ramsay to remain with the company through the interim period and align his interests with shareholders. For industry competitors, this change may indicate a period of strategic assessment or potential shifts in financial priorities at Halozyme. The market will be watching to see if this leadership change impacts Halozyme's ongoing collaborations and pipeline development.

This post was automatically generated from an SEC 8-K filing.